Argenica Therapeutics LtdASX: AGN

Notification of cessation of securities - AGN

Aug 13, 2026 at 3:32 AM EDT · Issued by Argenica Therapeutics Ltd via ASX

Filed with ASX · Aug 13, 2026 at 3:32 AM EDT · 4 pages · English

On 6ix: 6ix.com/news/notification-of-cessation-of-securities-agn

Release

Appendix 3H - Notification of cessation of securities Appendix 3H - Notification of cessation of securities 1 / 4 Announcement Summary Entity name ARGENICA THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Thursday August 13, 2026 Details of +securities...

Argenica Therapeutics Ltd on 6ix

Earlier from Argenica Therapeutics

ARG007 Shows Significant Neuroprotection in Concussion StudyJul 15
ARG007 (Xaranetide) Completes All Three FDA Requested AssaysJun 10
WHO Confirms Xaranetide as INN for ARG-007Jun 9
IND Application Advanced With Successful Completion of AssayMay 20
Clinical Advisory Committee Established to Advance Phase 2bMay 13

Later from Argenica Therapeutics

Appendix 4G & Corporate Governance StatementAug 26
Appendix 4E & Annual Report to 30 June 2026Aug 26
Concussion Data Selected for Neurotrauma CongressSep 14
AGM Date & Closing Date for Director NominationsSep 22
Change of Director's Interest NoticeSep 28

All Argenica Therapeutics news releases

Follow Argenica Therapeutics into a list and get an email when it puts out news.

Follow Argenica Therapeutics